Discrimination of haptens from prohaptens using the metabolically deficient Cprlow/low mouse

Toxicology and Applied Pharmacology

Volumn 252, Issue 3, 2011, Pages 268-272

  Chipinda, Itai ^a   Blachere, Francoise M ^a   Anderson, Stacey E ^a   Siegel, Paul D ^a  

^a NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH   (United States)

Author keywords

Cutaneous metabolism; Hapten; Prohapten; Skin sensitizers

Indexed keywords

4 ETHOXYMETHYLENE 2 PHENYL 2 OXAZOLIN 5 ONE; BENZO[A]PYRENE; CARVONE; CONTACT ALLERGEN; CYTOCHROME P450 REDUCTASE; HAPTEN; N ACETYLBENZOQUINONEIMINE; OXAZOLONE; OXIME DERIVATIVE; PARACETAMOL; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HETEROZYGOSITY; HOMOZYGOSITY; LOCAL LYMPH NODE ASSAY; LYMPHOCYTE; MALE; MOUSE; NONHUMAN;

ALLERGENS; ANIMALS; FEMALE; HAPTENS; LOCAL LYMPH NODE ASSAY; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NADPH-FERRIHEMOPROTEIN REDUCTASE; SKIN;

MURINAE; MUS;

EID: 79954629870     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2011.02.018     Document Type: Article

References (25)

1. Ahmad N., Mukhtar H. Cytochrome p450: a target for drug development for skin diseases. J. Invest. Dermatol. 2004, 123:417-425.
2. Ashby J., Hilton J., Dearman R.J., Callander R.D., Kimber I. Mechanistic relationship among mutagenicity, skin sensitization, and skin carcinogenicity. Environ. Health Perspect. 1993, 101:62-67.
3. Baron J.M., Holler D., Schiffer R., Frankenberg S., Neis M., Merk H.F., Jugert F.K. Expression of multiple cytochrome p450 enzymes and multidrug resistance-associated transport proteins in human skin keratinocytes. J. Invest. Dermatol. 2001, 116:541-548.
4. Bergstrom M.A., Ott H., Carlsson A., Neis M., Zwadlo-Klarwasser G., Jonsson C.A., Merk H.F., Karlberg A.T., Baron J.M. A skin-like cytochrome P450 cocktail activates prohaptens to contact allergenic metabolites. J. Invest. Dermatol. 2007, 127:1145-1153.
5. Bickers D.R., Mukhtar H., Dutta-Choudhury T., Marcelo C.L., Voorhees J.J. Aryl hydrocarbon hydroxylase, epoxide hydrolase, and benzo[a]-pyrene metabolism in human epidermis: comparative studies in normal subjects and patients with psoriasis. J. Invest. Dermatol. 1984, 83:51-56.
6. Bigger C.A., Sawicki J.T., Blake D.M., Raymond L.G., Dipple A. Products of binding of 7,12-dimethylbenz(a)anthracene to DNA in mouse skin. Cancer Res. 1983, 43:5647-5651.
7. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72:248-254.
8. Chipinda I., Ruwona T.B., Templeton S.P., Siegel P.D. Use of the Human Monocytic Leukemia THP-1 Cell Line and Co-incubation with Microsomes to Identify and Differentiate Hapten and Prohapten Sensitizers. Toxicology 2011, 280:135-143.
9. Gerberick G.F., Ryan C.A., Kern P.S., Schlatter H., Dearman R.J., Kimber I., Patlewicz G.Y., Basketter D.A. Compilation of historical local lymph node data for evaluation of skin sensitization alternative methods. Dermatitis 2005, 16:157-202.
10. Gerberick G.F., Troutman J.A., Foertsch L.M., Vassallo J.D., Quijano M., Dobson R.L., Goebel C., Lepoittevin J.P. Investigation of peptide reactivity of pro-hapten skin sensitizers using a peroxidase-peroxide oxidation system. Toxicol. Sci. 2009, 112:164-174.
11. Gibbs S., van de Sandt J.J., Merk H.F., Lockley D.J., Pendlington R.U., Pease C.K. Xenobiotic metabolism in human skin and 3D human skin reconstructs: a review. Curr. Drug Metab. 2007, 8:758-772.
12. Gu J., Weng Y., Zhang Q.Y., Cui H., Behr M., Wu L., Yang W., Zhang L., Ding X. Liver-specific deletion of the NADPH-cytochrome P450 reductase gene: impact on plasma cholesterol homeostasis and the function and regulation of microsomal cytochrome P450 and heme oxygenase. J. Biol. Chem. 2003, 278:25895-25901.
13. Guengerich F.P. Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem. Res. Toxicol. 2001, 14:611-650.
14. Guengerich F.P., Martin M.V., Sohl C.D., Cheng Q. Measurement of cytochrome P450 and NADPH-cytochrome P450 reductase. Nat. Protoc. 2009, 4:1245-1251.
15. Haneke K.E., Tice R.R., Carson B.L., Margolin B.H., Stokes W.S. ICCVAM evaluation of the murine local lymph node assay. Data analyses completed by the National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods. Regul. Toxicol. Pharmacol. 2001, 34:274-286.
16. Henderson K.S. Murine norovirus, a recently discovered and highly prevalent viral agent of mice. Lab. Anim. (NY) 2008, 37:314-320.
17. Henderson C.J., Otto D.M., Carrie D., Magnuson M.A., McLaren A.W., Rosewell I., Wolf C.R. Inactivation of the hepatic cytochrome P450 system by conditional deletion of hepatic cytochrome P450 reductase. J. Biol. Chem. 2003, 278:13480-13486.
18. Jowsey I.R., Basketter D.A., Westmoreland C., Kimber I. A future approach to measuring relative skin sensitising potency: a proposal. J. Appl. Toxicol. 2006, 26:341-350.
19. Merk H.F. Drug skin metabolites and allergic drug reactions. Curr. Opin. Allergy Clin. Immunol. 2009, 9:311-315.
20. Nilsson A.M., Bergstrom M.A., Luthman K., Nilsson J.L., Karlberg A.T. An alpha, beta-unsaturated oxime identified as a strong contact allergen. Indications of antigen formation via several pathways. Food Chem. Toxicol. 2005, 43:1627-1636.
21. Oldfield N. The metabolic fate of 13-cis-retinoic acid in mouse skin microsomal preparations. Drug Metab. Dispos. 1990, 18:1105-1107.
22. Ott H., Bergstrom M.A., Heise R., Skazik C., Zwadlo-Klarwasser G., Merk H.F., Baron J.M., Karlberg A.T. Cutaneous metabolic activation of carvoxime, a self-activating, skin-sensitizing prohapten. Chem. Res. Toxicol. 2009, 22:399-405.
23. Smith Pease C.K., Basketter D.A., Patlewicz G.Y. Contact allergy: the role of skin chemistry and metabolism. Clin. Exp. Dermatol. 2003, 28:177-183.
24. Woolhiser M.R., Munson A.E., Meade B.J. Comparison of mouse strains using the local lymph node assay. Toxicology 2000, 146:221-227.
25. Wu L., Gu J., Cui H., Zhang Q.Y., Behr M., Fang C., Weng Y., Kluetzman K., Swiatek P.J., Yang W., Kaminsky L., Ding X. Transgenic mice with a hypomorphic NADPH-cytochrome P450 reductase gene: effects on development, reproduction, and microsomal cytochrome P450. J. Pharmacol. Exp. Ther. 2005, 312:35-43.